Literature DB >> 10209813

Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error.

A Yafune1, M Ishiguro.   

Abstract

In population pharmacokinetic studies, one of the main objectives is to estimate population pharmacokinetic parameters specifying the population distributions of pharmacokinetic parameters. Confidence intervals for population pharmacokinetic parameters are generally estimated by assuming the asymptotic normality, which is a large-sample property, that is, a property which holds for the cases where sample sizes are large enough. In actual clinical trials, however, sample sizes are limited and not so large in general. Likelihood functions in population pharmacokinetic modelling include a multiple integral and are quite complicated. We hence suspect that the sample sizes of actual trials are often not large enough for assuming the asymptotic normality and that the asymptotic confidence intervals underestimate the uncertainties of the estimates of population pharmacokinetic parameters. As an alternative to the asymptotic normality approach, we can employ a bootstrap approach. This paper proposes a bootstrap standard error approach for constructing confidence intervals for population pharmacokinetic parameters. Comparisons between the asymptotic and bootstrap confidence intervals are made through applications to a simulated data set and an actual phase I trial.

Mesh:

Year:  1999        PMID: 10209813     DOI: 10.1002/(sici)1097-0258(19990315)18:5<581::aid-sim47>3.0.co;2-1

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  40 in total

1.  Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.

Authors:  Y Merlé; M Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

Review 2.  Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.

Authors:  J V Gobburu; P J Marroum
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs.

Authors:  Soo-Han Lee; Hyun-Ji Kang; Seok-Joon Jin; Do-Yang Park; Yoon-Ji Choi; Byung-Moon Choi; Eun-Kyung Lee; Gyu-Jeong Noh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-24       Impact factor: 2.745

4.  Population pharmacokinetic analysis of varenicline in adult smokers.

Authors:  Patanjali Ravva; Marc R Gastonguay; Thomas G Tensfeldt; Hélène M Faessel
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

5.  Characterization of the time course of carbamazepine deinduction by an enzyme turnover model.

Authors:  Baralee Punyawudho; James C Cloyd; Ilo E Leppik; R Eugene Ramsay; Susan E Marino; Page B Pennell; James R White; Angela K Birnbaum
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery.

Authors:  Camille Riff; Aurélie Bourgoin; Amelie Marsot; Laurent Allanioux; Marc Leone; Olivier Blin; Romain Guilhaumou
Journal:  Eur J Clin Pharmacol       Date:  2018-06-16       Impact factor: 2.953

7.  Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics.

Authors:  Pyry A Välitalo; Heidi Kemppainen; Aida Kulo; Anne Smits; Kristel van Calsteren; Klaus T Olkkola; Jan de Hoon; Catherijne A J Knibbe; Karel Allegaert
Journal:  Br J Clin Pharmacol       Date:  2017-05-14       Impact factor: 4.335

8.  Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

Authors:  Esther J H Janssen; Diane E T Bastiaans; Pyry A J Välitalo; Annemarie M C van Rossum; Evelyne Jacqz-Aigrain; Hermione Lyall; Catherijne A J Knibbe; David M Burger
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

9.  Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.

Authors:  Pei Hu; Jia Chen; Dongyang Liu; Xin Zheng; Qian Zhao; Ji Jiang
Journal:  Eur J Clin Pharmacol       Date:  2015-05-21       Impact factor: 2.953

10.  Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers.

Authors:  Carol Cronenberger; Diane R Mould; Hans-Juergen Roethig; Mohamadi Sarkar
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.